Filing Details

Accession Number:
0001562180-22-001435
Form Type:
4/A
Zero Holdings:
No
Publication Time:
2022-02-11 21:41:28
Reporting Period:
2020-06-15
Accepted Time:
2022-02-11 21:41:28
Original Submission Date:
2020-06-17
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1704234 Declan Doogan C/O Biohaven Pharmaceuticals, Inc.
215 Church Street
New Haven CT 06510
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2020-06-15 2,464 $67.83 726,002 No 4 S Indirect By the Declan Doogan 2014 Trust
Common Shares Disposition 2020-06-15 13,334 $68.15 333,912 No 4 S Direct
Common Shares Disposition 2020-06-16 15,508 $68.58 676,002 No 4 S Indirect By the Declan Doogan 2014 Trust
Common Shares Disposition 2020-06-16 10,000 $68.97 323,912 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By the Declan Doogan 2014 Trust
No 4 S Direct
No 4 S Indirect By the Declan Doogan 2014 Trust
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 - $67.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  2. This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.86 - $68.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 - $68.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.77 - $69.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.